Education
About Us
Working with TipRanks
Follow Us
PJP - ETF AI Analysis
Top Page
Invesco Dynamic Pharmaceuticals ETF (PJP)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several top holdings, including AbbVie, Johnson & Johnson, and Gilead Sciences, have delivered strong year-to-date performance, supporting the ETF’s overall returns.
Sector Focus on Health Care
The ETF’s focus on the health care sector provides exposure to a defensive industry that tends to perform well during economic uncertainty.
Solid Year-to-Date Performance
The ETF has shown strong year-to-date growth, indicating positive momentum in its portfolio.
Negative Factors
High Sector Concentration
The ETF is heavily concentrated in the health care sector, which limits diversification and increases exposure to industry-specific risks.
Weak Performance of Some Holdings
Key holdings like Merck and Pfizer have underperformed year-to-date, which could drag on overall returns.
Limited Geographic Exposure
The ETF is almost entirely focused on U.S. companies, offering little diversification across global markets.
PJP vs. SPDR S&P 500 ETF (SPY)
AUM313.05M
RegionNorth America
Expense Ratio0.57%
Beta0.55
IssuerInvesco
Inception DateJun 23, 2005
Dividend Yield0.94%
Asset ClassEquity
Index TrackedDynamic Pharmaceutical Intellidex Index (AMEX)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume12,452
30 Day Avg. Volume10,084
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
124.98Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PJP Summary
The Invesco Dynamic Pharmaceuticals ETF (PJP) is a fund that focuses on companies in the pharmaceutical industry, which is part of the broader health care sector. It tracks the Dynamic Pharmaceutical Intellidex Index and includes well-known companies like AbbVie and Eli Lilly. This ETF is designed for investors who want to benefit from the growth potential of pharmaceutical innovations, driven by factors like drug discovery and an aging population. It also offers diversification within the pharmaceutical space by spreading investments across multiple companies. However, new investors should be aware that the ETF’s performance is heavily tied to the health care sector, which can be impacted by regulatory changes and market conditions.
How much will it cost me?The Invesco Dynamic Pharmaceuticals ETF (PJP) has an expense ratio of 0.57%, meaning you’ll pay $5.70 per year for every $1,000 invested. This cost is higher than average because it’s actively managed, focusing on selecting pharmaceutical stocks based on various strategic factors to optimize performance.
What would affect this ETF?The Invesco Dynamic Pharmaceuticals ETF (PJP) could benefit from advancements in drug discovery, regulatory approvals, and the growing demand for pharmaceuticals driven by an aging population. However, it may face challenges from stricter regulations, patent expirations, or pricing pressures in the U.S. market, where it is heavily focused. The performance of its top holdings, such as AbbVie and Eli Lilly, will also play a significant role in shaping its future returns.
PJP Top 10 Holdings
The Invesco Dynamic Pharmaceuticals ETF (PJP) is heavily concentrated in the U.S. pharmaceuticals sector, with a mix of established giants and emerging players driving its performance. Eli Lilly and Travere Therapeutics are rising stars, with strong growth momentum and promising pipelines boosting the fund. Meanwhile, Pfizer and Abbott Laboratories are lagging, weighed down by weak revenue trends and cautious technical signals. The fund’s focus on innovation and drug development positions it well for long-term growth, but its reliance on a few key names and the sector’s inherent volatility could create bumps along the way.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Johnson & Johnson | 5.15% | $16.20M | $509.76B | 44.30% | 78 Outperform | |
| Pfizer | 5.14% | $16.17M | $146.98B | 1.06% | 74 Outperform | |
| Merck & Company | 5.01% | $15.76M | $248.95B | -1.67% | 80 Outperform | |
| Abbott Laboratories | 4.95% | $15.56M | $218.16B | 10.65% | 73 Outperform | |
| AbbVie | 4.88% | $15.35M | $394.69B | 28.81% | 66 Neutral | |
| Gilead Sciences | 4.82% | $15.16M | $149.38B | 31.08% | 78 Outperform | |
| Eli Lilly & Co | 4.82% | $15.15M | $971.39B | 30.21% | 72 Outperform | |
| Amgen | 4.77% | $15.00M | $171.10B | 17.41% | 77 Outperform | |
| Ocular Therapeutix | 3.34% | $10.52M | $3.10B | 67.55% | 55 Neutral | |
| Harmony Biosciences Holdings | 3.19% | $10.04M | $2.33B | 25.07% | 81 Outperform |
PJP Technical Analysis
Positive
―
Price Trends
99.39
Positive
94.33
Positive
87.65
Positive
Market Momentum
1.72
Positive
65.00
Neutral
70.46
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PJP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 104.67, equal to the 50-day MA of 99.39, and equal to the 200-day MA of 87.65, indicating a bullish trend. The MACD of 1.72 indicates Positive momentum. The RSI at 65.00 is Neutral, neither overbought nor oversold. The STOCH value of 70.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PJP.
PJP Peer Comparison
Comparison Results
Performance Comparison
PJP
Invesco Dynamic Pharmaceuticals ETF
105.88
22.28
26.65%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents